Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Assets (2020 - 2025)

Insight Molecular Diagnostics' Return on Assets history spans 6 years, with the latest figure at 1.3% for Q3 2025.

  • For Q3 2025, Return on Assets fell 92.0% year-over-year to 1.3%; the TTM value through Sep 2025 reached 1.3%, down 92.0%, while the annual FY2024 figure was 1.11%, 108.0% down from the prior year.
  • Return on Assets for Q3 2025 was 1.3% at Insight Molecular Diagnostics, down from 1.15% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.04% in Q4 2023 and bottomed at 1.3% in Q3 2025.
  • The 5-year median for Return on Assets is 0.41% (2021), against an average of 0.51%.
  • The largest YoY upside for Return on Assets was 43bps in 2024 against a maximum downside of -112bps in 2024.
  • A 5-year view of Return on Assets shows it stood at 0.41% in 2021, then fell by -2bps to 0.42% in 2022, then surged by 91bps to 0.04% in 2023, then plummeted by -2993bps to 1.16% in 2024, then dropped by -12bps to 1.3% in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Return on Assets are 1.3% (Q3 2025), 1.15% (Q2 2025), and 1.23% (Q1 2025).